TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (Nasdaq:CGEN) announced today that it will present experimental results for its previously disclosed CGEN-241 therapeutic candidate, a splice variant of c-Met receptor, at GTCBio’s Cancer Drugs Research & Development Conference (February 8-9, 2007, Philadelphia, PA).
